Interstitial Lung Disease

Interstitial lung disease (ILD) is a group of more than 200 rare lung disorders characterized by inflammation and scarring of the lung tissue. This scarring (fibrosis) can make breathing increasingly difficult and significantly reduce quality of life.

Approximately 655,000 adults in the United States currently struggle with ILD.

At Texas IPS, our dedicated ILD Clinic provides comprehensive care delivered by physicians with deep expertise in diagnosing and managing interstitial lung disease. Accurate diagnosis can be complex and challenging, which is why our multidisciplinary team includes pulmonologists, radiologists, pathologists, and rheumatologists who collaborate to ensure precise diagnosis and personalized treatment.

How we diagnose with precision:

1. High‑Resolution CT (HRCT)
2. Comprehensive Serologies & Genetics
3. Physiology & Exercise Testing
4. Minimally‑Invasive Tissue Sampling
5. Occupational & Environmental Assessments

Early diagnosis and specialized care are essential. At Texas IPS, patients benefit from advanced diagnostics, state-of-the-art therapies including antifibrotic treatments, and ongoing support.

Texas IPS leads a city-wide multidisciplinary ILD conference, bringing together specialists to advance research and improve outcomes.

At Texas IPS, our goal is clear: to improve quality of life, slow disease progression, and provide patients with clarity, comfort, and expert guidance at every stage of their ILD journey.

Evidence‑based treatment pathways include:

• Antifibrotic agents (nintedanib, pirfenidone) to slow decline in IPF.
• Targeted immunosuppression for inflammatory or connective‑tissue–related ILD.
• Pulmonary Rehabilitation—proven to improve exercise capacity and dyspnea.
• Oxygen Therapy Management and tele‑monitoring for home safety.
• Early Transplant Referral in collaboration with nationally ranked programs.